000096184 001__ 96184
000096184 005__ 20210902121838.0
000096184 0247_ $$2doi$$a10.1021/acs.jmedchem.0c00781
000096184 0248_ $$2sideral$$a120397
000096184 037__ $$aART-2020-120397
000096184 041__ $$aeng
000096184 100__ $$aPérez-López, A.M.
000096184 245__ $$aBioorthogonal Uncaging of Cytotoxic Paclitaxel through Pd Nanosheet-Hydrogel Frameworks
000096184 260__ $$c2020
000096184 5060_ $$aAccess copy available to the general public$$fUnrestricted
000096184 5203_ $$aThe promising potential of bioorthogonal catalysis in biomedicine is inspiring incremental efforts to design strategies that regulate drug activity in living systems. To achieve this, it is not only essential to develop customized inactive prodrugs and biocompatible metal catalysts but also the right physical environment for them to interact and enable drug production under spatial and/or temporal control. Toward this goal, here, we report the first inactive precursor of the potent broad-spectrum anticancer drug paclitaxel (a.k.a. Taxol) that is stable in cell culture and labile to Pd catalysts. This new prodrug is effectively uncaged in cancer cell culture by Pd nanosheets captured within agarose and alginate hydrogels, providing a biodegradable catalytic framework to achieve controlled release of one of the most important chemotherapy drugs in medical practice. The compatibility of bioorthogonal catalysis and physical hydrogels opens up new opportunities to administer and modulate the mobility of transition metal catalysts in living environs.
000096184 536__ $$9info:eu-repo/grantAgreement/EC/H2020/658833/EU/Development of Palladium-Labile Prodrugs for Bioorthogonally-Activated Chemotherapy/ChemoBOOM$$9This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 658833-ChemoBOOM$$9info:eu-repo/grantAgreement/EC/H2020/749299/EU/Integrated drug discovery approach to generate brain-penetrant inhibitors of glioblastoma cell proliferation/BRAINHIB$$9This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 749299-BRAINHIB$$9info:eu-repo/grantAgreement/ES/MICINN/RTI2018-099019-A-I00
000096184 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000096184 590__ $$a7.446$$b2020
000096184 591__ $$aCHEMISTRY, MEDICINAL$$b3 / 63 = 0.048$$c2020$$dQ1$$eT1
000096184 592__ $$a2.009$$b2020
000096184 593__ $$aMolecular Medicine$$c2020$$dQ1
000096184 593__ $$aDrug Discovery$$c2020$$dQ1
000096184 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000096184 700__ $$aRubio-Ruiz, B.
000096184 700__ $$aValero, T.
000096184 700__ $$aContreras-Montoya, R.
000096184 700__ $$aÁlvarez de Cienfuegos, L.
000096184 700__ $$0(orcid)0000-0002-6873-5244$$aSebastián, Víctor$$uUniversidad de Zaragoza
000096184 700__ $$0(orcid)0000-0002-8701-9745$$aSantamaría, Jesús$$uUniversidad de Zaragoza
000096184 700__ $$aUnciti-Broceta, A.
000096184 7102_ $$15005$$2555$$aUniversidad de Zaragoza$$bDpto. Ing.Quím.Tecnol.Med.Amb.$$cÁrea Ingeniería Química
000096184 773__ $$g63, 17 (2020), 9650-9659$$pJ. med. chem.$$tJournal of medicinal chemistry$$x0022-2623
000096184 8564_ $$s1447549$$uhttps://zaguan.unizar.es/record/96184/files/texto_completo.pdf$$yVersión publicada
000096184 8564_ $$s88453$$uhttps://zaguan.unizar.es/record/96184/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000096184 909CO $$ooai:zaguan.unizar.es:96184$$particulos$$pdriver
000096184 951__ $$a2021-09-02-10:22:03
000096184 980__ $$aARTICLE